Particle.news
Download on the App Store
7 ARTICLES
·
2w ago

GSK Reports Q2 Beat and Unveils £1.9 Billion Savings Plan

The plan frees capital for late-stage development to accelerate more than 20 planned Phase III starts, protecting margins as dolutegravir faces expected generic competition.

Not for general use, only in relation to communications for specific GLT member. 5 years BTL use only.
The cost-cutting measures follow having to abandon development of a chronic cough treatment that was in final stage trials
Image
Image

Overview

  • GSK posted a second-quarter core earnings beat on Tuesday with turnover of £8.41 billion, core operating profit of £2.8 billion, and core EPS of 50.5 pence, driven by Specialty Medicines and Vaccines.
  • The company launched a three-year efficiency programme targeting £1.9 billion in annual savings by 2029 with an estimated £2.4 billion execution cost to free funds for late-stage trials.
  • GSK took a £1.3 billion impairment after halting camlipixant following Phase III results that showed limited efficacy, a charge that pushed statutory net profit down about 70% to £435 million.
  • Management said the bulk of savings will be reinvested in R&D, including a £400 million Cambridge centre to open by 2029, and the firm plans to start more than 20 Phase III trials this year.
  • The moves follow GSK’s June acquisition of Nuvalent to build oncology capacity and reflect a push to protect margins and hit long-term growth targets as key HIV patents approach generic entry between 2028 and 2030.